X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (421) 421
Publication (78) 78
Patent (12) 12
Book Chapter (3) 3
Book / eBook (2) 2
Book Review (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (157) 157
oncology (137) 137
index medicus (136) 136
female (97) 97
male (93) 93
middle aged (85) 85
aged (81) 81
adult (69) 69
cancer (69) 69
article (62) 62
chemotherapy (52) 52
aged, 80 and over (48) 48
pancreatic cancer (45) 45
antineoplastic combined chemotherapy protocols - therapeutic use (44) 44
treatment outcome (44) 44
gemcitabine (39) 39
colorectal cancer (35) 35
medicine & public health (31) 31
survival (31) 31
adenocarcinoma (30) 30
neoplasm staging (30) 30
surgery (29) 29
care and treatment (28) 28
therapy (28) 28
deoxycytidine - analogs & derivatives (27) 27
pancreatic neoplasms - pathology (27) 27
research (26) 26
prognosis (25) 25
pancreatic neoplasms - drug therapy (24) 24
retrospective studies (24) 24
metastasis (23) 23
pharmacology & pharmacy (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
clinical trials (22) 22
bevacizumab (21) 21
tumors (21) 21
deoxycytidine - administration & dosage (20) 20
disease-free survival (20) 20
drug therapy (20) 20
survival rate (20) 20
neoplasm metastasis (19) 19
abridged index medicus (18) 18
combined modality therapy (17) 17
oxaliplatin (17) 17
trial (17) 17
1st-line treatment (16) 16
adenocarcinoma - pathology (16) 16
adjuvant chemotherapy (16) 16
analysis (16) 16
antineoplastic agents - therapeutic use (16) 16
cancer therapies (16) 16
carcinoma (16) 16
health aspects (16) 16
kaplan-meier estimate (16) 16
mutation (16) 16
phase-iii trial (16) 16
animals (15) 15
colorectal neoplasms - pathology (15) 15
fluorouracil (15) 15
maximum tolerated dose (15) 15
patients (15) 15
young adult (15) 15
camptothecin - analogs & derivatives (14) 14
cetuximab (14) 14
metastases (14) 14
pharmacology/toxicology (14) 14
adenocarcinoma - drug therapy (13) 13
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
apoptosis (13) 13
colorectal neoplasms - drug therapy (13) 13
dose-response relationship, drug (13) 13
immunotherapy (13) 13
neoplasms - drug therapy (13) 13
prospective studies (13) 13
cell line, tumor (12) 12
colorectal-cancer (12) 12
drug administration schedule (12) 12
fluorouracil - administration & dosage (12) 12
human necessities (12) 12
hygiene (12) 12
medical or veterinary science (12) 12
neoadjuvant therapy (12) 12
neoplasms. tumors. oncology. including cancer and carcinogens (12) 12
organoplatinum compounds - administration & dosage (12) 12
pancreatic neoplasms - mortality (12) 12
preparations for medical, dental, or toilet purposes (12) 12
usage (12) 12
camptothecin - administration & dosage (11) 11
cancer research (11) 11
capecitabine (11) 11
combination (11) 11
deoxycytidine - adverse effects (11) 11
dosage and administration (11) 11
follow-up studies (11) 11
gastroenterology & hepatology (11) 11
gastrointestinal cancer (11) 11
hematology, oncology and palliative medicine (11) 11
patient outcomes (11) 11
review (11) 11
solid tumors (11) 11
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (439) 439
French (6) 6
German (2) 2
Chinese (1) 1
Korean (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2018, ISBN 9783319582559
This book provides a comprehensive, state-of-the art review of current and new therapies in treating pancreatic cancer. In addition to discussing the current... 
Medicine | Hepatology | Gastroenterology | Oncology
Web Resource
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 446 - 453
Journal Article
The Oncologist, ISSN 1083-7159, 01/2018, Volume 23, Issue 1, pp. 25 - 34
摘要 靶向治疗的出现大大提高了转移性结直肠癌(mCRC)的生存率, 但同时也导致难以识别多种mCRC治疗药物的最佳顺序和组合的困境。包括伊立替康、奥沙利铂、5‐氟尿嘧啶、卡培他滨和TAS‐102在内的多种细胞毒性药物可以用于治疗mCRC。此外, 尽管罹患大鼠肉瘤病毒癌基因同源物( RAS... 
Molecular targeted therapy | Antineoplastic protocols | Colorectal neoplasms | Patient selection | Investigational therapies | Combination drug therapy | 1ST-LINE TREATMENT | REGORAFENIB PLUS | MODIFIED FOLFOX6 | BEVACIZUMAB | OPEN-LABEL | CHEMOTHERAPY | ONCOLOGY | RANDOMIZED PHASE-III | FOLFIRI PLUS CETUXIMAB | 2ND-LINE TREATMENT | DOUBLE-BLIND | Gastrointestinal Cancer
Journal Article
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 10/2018, Volume 16, Issue 10, pp. 667 - 669
Journal Article
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 09/2018, Volume 16 Suppl 18, Issue 9, p. 2
Journal Article
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 09/2018, Volume 16 Suppl 17, Issue 9, p. 5
Journal Article
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 09/2018, Volume 16 Suppl 17, Issue 9, p. 7
Journal Article
Clinical advances in hematology & oncology : H&O, ISSN 1543-0790, 03/2018, Volume 16, Issue 3, pp. 16 - 18
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 12/2017, Volume 15, Issue 12, pp. 16 - 20
Journal Article
Clinical Advances in Hematology and Oncology, ISSN 1543-0790, 11/2017, Volume 15, Issue 11, pp. 11 - 14
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 8, pp. 1303 - 1312
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10018, pp. 545 - 557
Summary Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated... 
Internal Medicine | PLUS GEMCITABINE | SURVIVAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | ADENOCARCINOMA | 2ND-LINE CHEMOTHERAPY | OXALIPLATIN | PEP02 | DOCETAXEL | CARCINOMA | FOLFIRI | Leucovorin - administration & dosage | Humans | Middle Aged | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Pancreatic Neoplasms - drug therapy | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Camptothecin - administration & dosage | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Irinotecan | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Liposomes | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Pancreatic cancer | Leucovorin | Product development | Research institutes | Metastasis | Antineoplastic agents | Analysis | Antigens | Chemotherapy | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Tumors | Adenocarcinoma | Slopes | Therapy | Gemcitabine | Toxicity | Metastases | Nanoparticles | Randomization | Motivation | Vomiting | Safety management | Toxic diseases | Neutropenia | Folinic acid | Lymphatic system | Medical treatment | Diarrhea | FDA approval | Survival | Patients | Acids | Equivalence | Interactive systems
Journal Article
Journal Article
09/2017, 1st ed. 2018, ISBN 9783319582559, 381
This book provides a comprehensive, state-of-the art review of current and new therapies in treating pancreatic cancer. In addition to discussing the current... 
Pancreas | Cancer
eBook
Future Oncology, ISSN 1479-6694, 04/2018, Volume 14, Issue 10, pp. 901 - 906
Napabucasin is a novel oral first-in-class cancer stemness inhibitor. Preclinical and early phase clinical trials showed promising antitumor efficacy signals... 
gastric cancer | BBI608 | napabucasin | ONCOLOGY | DOCETAXEL | CANCER STEM-CELLS | PLUS | PACLITAXEL
Journal Article
Gut, ISSN 0017-5749, 02/2018, Volume 67, Issue 2, pp. 320 - 332
ObjectiveLimited efficacy of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma (PDAC) has prompted investigation into combination therapy. We... 
INTERLEUKINS | IMMUNOTHERAPY | PANCREATIC CANCER | MULTIPLE-MYELOMA | INTERFERON-ALPHA | ACTIVATION | ADENOCARCINOMA | SILTUXIMAB | MONOCLONAL-ANTIBODY | MICE | SUPPRESSOR-CELLS | INTERLEUKIN-6 | GASTROENTEROLOGY & HEPATOLOGY | T-CELLS | Antineoplastic Agents, Immunological - administration & dosage | Interleukin-6 - antagonists & inhibitors | Pancreatic Neoplasms - metabolism | Humans | Actins - metabolism | Carcinoma, Pancreatic Ductal - metabolism | STAT Transcription Factors - metabolism | Janus Kinases - metabolism | L-Selectin - metabolism | Pancreatic Neoplasms - drug therapy | Th1 Cells - metabolism | Pancreatic Stellate Cells - immunology | Hyaluronan Receptors - metabolism | Female | Lymphocytes, Tumor-Infiltrating - metabolism | Carcinoma, Pancreatic Ductal - immunology | Interleukin-6 - metabolism | Disease Models, Animal | Mice, Inbred C57BL | Survival Rate | B7-H1 Antigen - immunology | Disease Progression | Tumor Microenvironment - immunology | Xenograft Model Antitumor Assays | Carcinoma, Pancreatic Ductal - drug therapy | B7-H1 Antigen - metabolism | Animals | B7-H1 Antigen - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pancreatic Neoplasms - immunology | Interleukin-6 - immunology | Mice | Pancreatic Stellate Cells - metabolism | Adenocarcinoma | Immunohistochemistry | Flow cytometry | Animal models | Transcription | CD8 antigen | Multiple myeloma | Smooth muscle | Lymphocytes T | Kinases | Metastases | Interleukin 6 | Lymphocytes | Actin | CD44 antigen | Immunotherapy | Fibroblasts | BRCA2 protein | Stellate cells | Cytokines | Secretion | Stroma | CD62L protein | CD4 antigen | Immune checkpoint | Antibiotics | Pancreatic cancer | Medical prognosis | PD-L1 protein | Cell lines | Ligands | Genetic engineering | Apoptosis | PD-L1 | pancreatic cancer | IL-6
Journal Article